Logo image of FTCV

FINTECH ACQUISITION CORP V-A (FTCV) Stock Fundamental Analysis

NASDAQ:FTCV - Nasdaq - US31810Q1076 - Common Stock - Currency: USD

10.06  0 (-0.01%)

After market: 10.07 +0.01 (+0.1%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FTCV. FTCV was compared to 0 industry peers in the Unkown industry. While FTCV seems to be doing ok healthwise, there are quite some concerns on its profitability. FTCV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year FTCV was profitable.
In the past year FTCV has reported a negative cash flow from operations.
FTCV Yearly Net Income VS EBIT VS OCF VS FCFFTCV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 -1M -2M -3M

1.2 Ratios

Industry RankSector Rank
ROA 6.81%
ROE 7.22%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FTCV Yearly ROA, ROE, ROICFTCV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 -0.5 -1

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FTCV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FTCV Yearly Profit, Operating, Gross MarginsFTCV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

4

2. Health

2.1 Basic Checks

The number of shares outstanding for FTCV remains at a similar level compared to 1 year ago.
Compared to 1 year ago, FTCV has a worse debt to assets ratio.
FTCV Yearly Shares OutstandingFTCV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 10M 20M 30M
FTCV Yearly Total Debt VS Total AssetsFTCV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 14.20 indicates that FTCV is not in any danger for bankruptcy at the moment.
There is no outstanding debt for FTCV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.2
ROIC/WACCN/A
WACCN/A
FTCV Yearly LT Debt VS Equity VS FCFFTCV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.06 indicates that FTCV may have some problems paying its short term obligations.
FTCV has a Quick Ratio of 0.06. This is a bad value and indicates that FTCV is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
FTCV Yearly Current Assets VS Current LiabilitesFTCV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 500K 1M 1.5M 2M 2.5M

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 400.55% over the past year.
EPS 1Y (TTM)400.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FTCV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.22% yearly.
Based on estimates for the next years, FTCV will show a small growth in Revenue. The Revenue will grow by 4.09% on average per year.
EPS Next Y95.65%
EPS Next 2Y44.46%
EPS Next 3Y27.8%
EPS Next 5Y20.22%
Revenue Next Year-7.4%
Revenue Next 2Y4.27%
Revenue Next 3Y3.8%
Revenue Next 5Y4.09%

3.3 Evolution

FTCV Yearly Revenue VS EstimatesFTCV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
FTCV Yearly EPS VS EstimatesFTCV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 0 -0.05 -0.1 -0.15 -0.2

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 20.12, the valuation of FTCV can be described as rather expensive.
The average S&P500 Price/Earnings ratio is at 29.62. FTCV is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 493.14, the valuation of FTCV can be described as expensive.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, FTCV is valued quite expensively.
Industry RankSector Rank
PE 20.12
Fwd PE 493.14
FTCV Price Earnings VS Forward Price EarningsFTCV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FTCV Per share dataFTCV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FTCV's earnings are expected to grow with 27.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y44.46%
EPS Next 3Y27.8%

0

5. Dividend

5.1 Amount

No dividends for FTCV!.
Industry RankSector Rank
Dividend Yield N/A

FINTECH ACQUISITION CORP V-A

NASDAQ:FTCV (12/8/2022, 8:00:00 PM)

After market: 10.07 +0.01 (+0.1%)

10.06

0 (-0.01%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)03-06 2023-03-06
Inst Owners1.88%
Inst Owner Change0%
Ins Owners1.87%
Ins Owner Change0%
Market Cap343.92M
Analysts43.33
Price Target10.46 (3.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 20.12
Fwd PE 493.14
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)0.5
EY4.97%
EPS(NY)0.02
Fwd EY0.2%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS6.93
TBVpS6.93
PEG (NY)0.21
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.81%
ROE 7.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z 14.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.86%
EPS Next Y95.65%
EPS Next 2Y44.46%
EPS Next 3Y27.8%
EPS Next 5Y20.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-7.4%
Revenue Next 2Y4.27%
Revenue Next 3Y3.8%
Revenue Next 5Y4.09%
EBIT growth 1Y43.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.86%
EBIT Next 3Y33.03%
EBIT Next 5Y26%
FCF growth 1Y-142.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.98%
OCF growth 3YN/A
OCF growth 5YN/A